Amubarvimab, previously known as BRII-196 , represents a significant advancement in antibody development, particularly concerning its potential to block SARS-CoV-2 . This targeted molecule demonstrates https://gorillasocialwork.com/story27343937/amubarvimab-a-in-depth-dive-into-the-antibody-s-prospects